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Editor’s Note
Cynthia Chauhan is a patient advocate for the North
Central Cancer Treatment Group. She is also a cancer
patient with unique insights and articulate impressions
regarding the assessment of patient-reported outcomes
(PROs). The following is intended to tie together the
material in this body of work to remind all of us that
at the heart of all that we do in assessing PROs is a
human being. In short, it’s all about the patient.
A Patient Advocate’s Response
It has been my privilege to work with the Mayo/FDA
Patient-Reported Outcomes Consensus Meeting
Group, observing and learning how you as profession-
als view, interpret, and relate to my reality. You are all
obviously bright, well-intentioned, altruistic people
who are concerned about patient well-being, and I
thank you from the bottom of my heart not just for
myself but for all patients. I have watched you struggle
with concepts and ﬁght for opportunity and recogni-
tion. I want to respond to and perhaps invite you to
reframe some of the issues I have watched you address
and shy away from.
I know a lot about struggling, ﬁghting for opportu-
nity, and claiming recognition. I happen to be a patient
with multiple diagnoses related to each other only by
the fact that they share my body and shape my life
experience. They include two cancers, glaucoma, asth-
matic bronchitis, idiopathic neuropathy, and a few
others. But you get the picture.
First of all, I do understand this is an effort about
drug labeling and how to incorporate what the patient
reports are experienced as a result of using that drug in
the labeling. You name that patient experience “symp-
toms” and you have spent a great deal of time differ-
entiating or arguing against differentiating symptoms
from health-related quality of life (HRQL), much less
quality of life (QOL). I understand the need for par-
tializing in problem-solving as long as one holds onto
the knowledge that the whole is equal to and perhaps
greater than, the sum of its parts. In that context, I do
not think symptoms can be separated from those two
things, HRQL and QOL, in the real world.
The symptoms with which I live, some illness-
induced, some drug-induced, are real parts of my every
day life and they do affect my quality of life. They
affect how I go about my life and the expectations I can
reasonably set for myself and others. However, it is
equally important to note that the quality of my life
affects my tolerance for many of those symptoms. Dr.
Sloan of the Mayo Clinic has indicated elsewhere that
there is presently a controversy surrounding how to
measure hot ﬂashes activity that women may not per-
ceive [1]. An appropriate use of Dr. Sloan’s hot ﬂash
perceiver example would to be to use it to help women
look at and consider what is going on in their external
and internal environments when they do and do not
notice the ﬂashes.
Different symptoms affect me to different degrees,
and something you did not address is that the hypo-
thetical possibility of symptoms also affects me and
choices I make about medications. I know you said
that you deal in realities, by which I understand you to
mean concrete and quantiﬁable, not hypothetical situ-
ations; but hypotheticals do impinge on patients’ reali-
ties. For example, I use a drug called bimatoprost in
my left eye to forestall blindness from glaucoma. I have
had sapphire blue eyes all of my life. One of the side-
effects of bimatoprost in blue-eyed people is turning of
the iris to brown. On one level, it’s a no-brainer that I
will take the drug because going blind is worse than
having a brown eye. On another level, there is emo-
tional distress associated with potentially losing what
has been a positively deﬁning aspect of self. The eye
color change may not qualify as a PRO, but the dis-
tress does and it affects quality of life. I use this
example to urge you to consider and be wary that you
do not lose the whole person in your quest to give
PROs free-standing autonomy, but understand they
are an artiﬁcially extricated part of a complex whole.
On the other hand, I get seriously nauseated and
somnolent when I take one of my pain medicines and
experience cognitive deterioration when I take one of
the others, so I will tolerate a great deal of pain before
I resort to the medications because while they provide
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primary symptom control, their concomitant symptom
inducement seriously compromises my quality of life.
Symptoms and QOL are inextricably intertwined
for the patient. If I were to modify your theoretical
framework [2], I would put a large balloon for QOL
holding a smaller inset balloon for HRQL holding yet
a smaller one for symptoms. Or perhaps I would show
multiple smaller balloons of symptoms attenuating
and distorting the other balloons as they do our lives.
In your quest to differentiate and honor symptoms,
I caution and urge you not to validate the ancient
Indian tale of the nine blind men who sought to
describe an elephant by each touching one part of the
elephant. They did come up with interesting creative
descriptions and observations which each held to as
inviolably true. But, in fact, those observations did not
translate to the reality of the elephant. No matter how
much it wiggles, an elephant’s tail is never a snake.
Hence, I ask you to keep in mind the entire person
perspective as you do your valuable work on working
through the details of individual PRO assessment.
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